Latest Biotechnology, Pharmaceutical and Healthcare News from BioPharma-Reporter

13:09 EST 19th November 2017 | BioPortfolio

Here are the most relevant search results for "BioPharma-Reporter" found in our extensive news archives from over 250 global news sources.

More Information about BioPharma-Reporter on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioPharma-Reporter for you to read. Along with our medical data and news we also list BioPharma-Reporter Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharma-Reporter Companies for you to search.

Showing News Articles 1–25 of 338 from BioPharma-Reporter

Friday 17th November 2017

ABEC: customised tech protects large single-use bags

A pulley loading system and customised storage frame reduces damage risk to large single-use bags, says 4,000L bioreactor vendor ABEC.

‘No longer the stuff of science fiction’ – US FDA publishes regenerative med policies

The US FDA has published a series of guidelines to spur development of regenerative medicines while ensuing safety and efficacy of such products.

Biosimilar battles: J&J drops Remicade patent dispute against Samsung Bioepis

Janssen has withdrawn a lawsuit against Samsung Bioepis alleging infliximab manufacturing patent infringements after receiving process information from the Korean drugmaker.

Thursday 16th November 2017

Avid letting Peregrine fly off as it focuses on bio-CDMO business

Peregrine Pharmaceuticals will become a pure-play CDMO under the name Avid Biosciences and is looking to sell or license its pipeline, including investigational monoclonal antibody bavituximab.

Wednesday 15th November 2017

Pall partners Swiss training firm for continuous biomanufacturing

Pall Life Sciences will equip a training facility in Fribourg, Switzerland.with its continuous bioprocessing equipment.

J&J biospecific antibody deal could net Zymeworks up to $1.5bn

Janssen Biotech has selected Zymeworksâ Azymetric and Effect platforms to make bispecific antibody therapeutics.

J&J biospecific antibody deal could net Zymeworks up to $2.5bn

Janssen Biotech has selected Zymeworksâ Azymetric and Effect platforms to make bispecific antibody therapeutics.

Tuesday 14th November 2017

GE pumping up to $350m in Swedish site to support biopharma demand

GE Healthcare will invest $50-70m a year until 2022 in its bioprocessing equipment and consumables site in Uppsala, Sweden.

Boehringer’s success gives EU another Humira biosimilar

The European Commission (EC) has approved Boehringer Ingelheimâs Humira (adalimumab) biosimilar, Cyltezo.

Amgen drops two-brand Avastin biosimilar strategy in Europe

Mvasi has been recommended for approval in Europe, but a duplicate marketing authorisation application for an Avastin (bevacizumab) biosimilar has been withdrawn by Amgen.

Friday 10th November 2017

Merck KGaA: Extensive uptake of single-use forced efficiency drive

Single-use demand grew so fast vendors were unable to keep up, says MilliporeSigma which has since tackled this through investments and a standardised offering.

Vetter enters biologics ‘sweet spot’ through Korean office

Fill and finish CDMO Vetter says its newly opened sales office in Songdo will tap the large Korean biologics market.

InVitria launches xeno-free formulation service within $5.2bn media market

Xeno-free media will continue to increase its share of the estimated 30m litre mammalian cell culture market says InVitria, which has launched a new formulation service.

Wednesday 8th November 2017

Catalent: Cook deal strengthens sub 5,000L scale CMO strategy

70% of the biologics pipeline will require less than 5,000L of commercial manufacturing capacity says Catalent, fresh from its acquisition of Cook.

Samsung BioLogics extends supply agreement with MilliporeSigma

Samsung BioLogics has extended a memorandum of understanding with MilliporeSigma for supply of single-use systems and bioprocessing raw materials.

Tuesday 7th November 2017

Roche: 130 jobs to go at Vacaville, California site

Roche will eliminate 130 jobs at a biomanufacturing plant in Vacaville, California.

Supply chain security in the buffer bag? Biopharma expert calls for a standardised design

Standardising disposable bioreactor technology â starting with the buffer bag â will help ensure single-use supply chain security, says biomanufacturing consultant David Wolton.

Swiss CDMO to expand newly bought Glycotope biomanufacturing plant in Germany

Celonic says it will immediately begin expanding the former Glycotope site in Heidelberg, Germany adding two 2,000L single-use bioreactors.

Monday 6th November 2017

Fujifilm adding three 2,000L GE single-use bioreactors as part of $30m expansion

Following a âÂ14bn ($125m) investment in April, Fujifilm Corporation has committed a further âÂ3.2bn across its biologics contract manufacturing business.

Friday 3rd November 2017

Purolite teams with Repligen for prefilled Protein A columns

Purolite Life Sciences will offer its Protein A resin prefilled in Repligenâs chromatography columns through a partnership between the two firms.

Pall lands Wuxi fit out for mAb continuous bioprocess lab

Pall Corporation will equip Wuxi Biologicsâ continuous bioprocess laboratory in a joint venture, which the latter said would expand process scale and reduce manufacturing costs.

Juno: Centralised approach key to manufacturing CAR T therapies

Heavy investment in quality control, quality assurance and dedicated equipment is likely to keep CAR T-cell manufacturing in-house, says Juno Therapeutics.

Bioprocessing survey report: Is the CHO CHO train slowing down?

Nearly half the respondents of our second state of the global biomanufacturing survey believe we are too reliant on Chinese Hamster Ovary (CHO) expression systems.

Tuesday 31st October 2017

Grid picks Catalent to make mAb for solid tumours

Grid Therapeutics has selected Catalent Pharma Solutions to develop and manufacture its antibody candidate to treat solid tumours.

Daiichi Sankyo inks Glycotope ADC deal

Daiichi Sankyo Company has signed an option agreement to develop Glycotopeâs antibody drug conjugate (ADC) to target various cancers including ovarian, lung and breast tumours.

Quick Search

News Quicklinks